Related Articles
Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas
IDH1 mutation of gliomas with long-term survival analysis
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy
S100A6 is a potential diagnostic and prognostic biomarker for human glioma
FOXL1 overexpression is associated with poor outcome in patients with glioma